Leukine
Total Payments
$3.9M
Transactions
865
Doctors
457
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $15,196 | 5 | 1 |
| 2023 | $956,006 | 18 | 1 |
| 2022 | $110,590 | 35 | 30 |
| 2021 | $528,129 | 51 | 17 |
| 2020 | $1.4M | 127 | 43 |
| 2019 | $508,607 | 411 | 300 |
| 2018 | $312,928 | 218 | 121 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.4M | 49 | 63.1% |
| Consulting Fee | $1.1M | 201 | 27.4% |
| Grant | $246,304 | 4 | 6.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,771 | 43 | 2.2% |
| Food and Beverage | $14,257 | 512 | 0.4% |
| Travel and Lodging | $13,980 | 43 | 0.4% |
| Education | $4,519 | 11 | 0.1% |
| Honoraria | $3,000 | 2 | 0.1% |
Payments by Type
Research
$2.4M
49 transactions
General
$1.4M
816 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Parkinsons II | Partner Therapeutics, Inc. | $792,299 | 0 |
| UNE Parkinsons | Partner Therapeutics, Inc. | $531,665 | 0 |
| Safety, Tolerability and Biomarker Assessments of Leukine During Extended Time Treatment for PD | Partner Therapeutics, Inc. | $267,251 | 0 |
| Sargarmostim Retrospective Chart Review | Partner Therapeutics, Inc. | $197,000 | 0 |
| UCSF Biliary | Partner Therapeutics, Inc. | $145,767 | 0 |
| PTI-001-005a | Partner Therapeutics, Inc. | $107,075 | 0 |
| Immunologic Assessment of cholangiosarcoma patients undergoing immunotherpay with GMCSF and pembrolizumab | Partner Therapeutics, Inc. | $100,000 | 0 |
| NS Haplo Transplant | Partner Therapeutics, Inc. | $79,887 | 0 |
| iLEUKPULM | Partner Therapeutics, Inc. | $79,038 | 0 |
| GM-CF in Peripheral Arterial Disease GPAD Study III | Partner Therapeutics, Inc. | $65,988 | 0 |
| Halpo ISR Study Northside Hospital | Partner Therapeutics, Inc. | $27,761 | 0 |
| G-PAD | Partner Therapeutics, Inc. | $26,122 | 0 |
| PAD | Partner Therapeutics, Inc. | $19,837 | 0 |
| Phase II GM-CSF + Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced NSCLC Pts w PDL-1 | Partner Therapeutics, Inc. | $1,542 | 0 |
| SCOPE | Partner Therapeutics, Inc. | $1,050 | 0 |
Top Doctors Receiving Payments for Leukine
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Altanta, GA | $2.7M | 60 |
| , MD | Hematology & Oncology | Cleveland, OH | $589,796 | 32 |
| , M.D | Neurology | Zionsville, IN | $36,455 | 17 |
| , M.D | Nephrology | Cambridge, MA | $34,470 | 5 |
| Robert Gale | Medical Oncology | Los Angeles, CA | $33,961 | 7 |
| , MD | Hematology & Oncology | Pittsburgh, PA | $18,302 | 5 |
| , MD | Hematology & Oncology | Omaha, NE | $17,419 | 6 |
| , M.D | Internal Medicine | Cincinnati, OH | $15,196 | 5 |
| , MD | Critical Care Medicine | Cleveland, OH | $14,671 | 2 |
| , MD | Critical Care Medicine | Los Angeles, CA | $13,276 | 6 |
| , MD | Medical Oncology | Durham, NC | $13,197 | 10 |
| , M.D | Internal Medicine | Bridgeport, CT | $12,875 | 2 |
| , MD | Rheumatology | Morrisville, NC | $12,000 | 7 |
| , MD | Internal Medicine | Los Angeles, CA | $11,701 | 4 |
| , M.D | Specialist | Canton, OH | $10,784 | 6 |
| , MD | Medical Oncology | Boston, MA | $10,750 | 2 |
| , M.D | Infectious Disease | Houston, TX | $10,073 | 4 |
| , MD | Medical Oncology | Seattle, WA | $9,384 | 6 |
| , M.D | Hematology & Oncology | Houston, TX | $9,250 | 3 |
| , MD | Infectious Disease | New York, NY | $9,173 | 4 |
| , M.D | Medical Oncology | Columbus, OH | $9,014 | 9 |
| , M.D | Critical Care Medicine | Gainesville, FL | $8,631 | 3 |
| , M.D | Hematology & Oncology | New York, NY | $8,510 | 10 |
| , MD | Pediatrics | Boston, MA | $8,000 | 1 |
| , M.D | Pediatric Hematology-Oncology | Boston, MA | $7,975 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 457
- Transactions 865
About Leukine
Leukine is a drug associated with $3.9M in payments to 457 healthcare providers, recorded across 865 transactions in the CMS Open Payments database. The primary manufacturer is Partner Therapeutics, Inc..
Payment data is available from 2018 to 2024. In 2024, $15,196 was paid across 5 transactions to 1 doctors.
The most common payment nature for Leukine is "Unspecified" ($2.4M, 63.1% of total).
Leukine is associated with 15 research studies, including "Parkinsons II" ($792,299).